Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC) August 5, 2021
Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics’ IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting June 2, 2021
Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors April 8, 2021
PORTAGE BIOTECH HIGHLIGHTS INITIATION OF THE INVINCIBLE TRIAL, A PHASE 2 EARLY STAGE BREAST CANCER STUDY FROM INTENSITY THERAPEUTICS March 25, 2021
PORTAGE BIOTECH PROVIDES RESEARCH AND DEVELOPMENT UPDATE AND ANNOUNCES NASDAQ LISTING APPROVAL February 11, 2021
PORTAGE ANNOUNCES FILING OF Q1 INTERIM FINANCIAL STATEMENTS; CORRECTION TO SALVARX LOAN NOTE SETTLEMENT ANNOUNCEMENT October 16, 2020
PORTAGE ISSUES COMMON SHARES AND WARRANTS IN SETTLEMENT OF SALVARX LOAN NOTE OBLIGATIONS October 13, 2020
PORTAGE ANNOUNCES RELIANCE ON TEMPORARY REGULATORY RELIEF FOR FILING ANNUAL FINANCIAL STATEMENTS July 28, 2020
PORTAGE ANNOUNCES RESULTS OF ANNUAL MEETING; PRIVATE PLACEMENT UPDATE; CORPORATE UPDATE June 26, 2020
PORTAGE RAISES MORE THAN US$6.7 MILLION THROUGH NON-BROKERED PRIVATE PLACEMENT; TEMPORARY SYMBOL CHANGE ON OTC MARKETS June 16, 2020
PORTAGE MAKES ADDITIONAL INVESTMENT IN STIMUNITY S.A.S, A PARIS-BASED CANCER IMMUNOTHERAPY COMPANY. May 11, 2020
Portage makes an additional investment in Saugatuck therapeutics after achieving proof of concept May 5, 2020
PORTAGE ANNOUNCES CEASE TRADE ORDER REVOKED; UPDATE ON IMPACT OF COVID-19 ON OPERATIONS April 16, 2020
PORTAGE ANNOUNCES FILING OF 3RD QUARTER FINANCIAL STATEMENTS AND PROVIDES UPDATE ON CTO REVOCATION APPLICATION AND OTC TRADING March 13, 2020
PORTAGE ANNOUNCES FURTHER SUBSCRIPTION OF US$950,000 IN CONVERTIBLE LOAN NOTES TO IOX THERAPEUTICS AND PROVIDES UPDATE ON CTO REVOCATION APPLICATION January 30, 2020
Portage Biotech Inc. (CSE: PBT.U, OTC Markets: PTGEF) (“Portage” or the “Company”) is pleased to announce that it has been granted an extension by the Canadian Securities Exchange (the “CSE”) to remedy its default under CSE listing rules. December 6, 2019
Portage makes additional investment in Stimunity S.A. a Paris-Based Cancer immunotherapy company March 25, 2019
Portage posts meeting materials; trading on CSE expected to resume shortly; overview of combined Portage/SalvaRx portfolio November 18, 2018
Portage Announces Results of Shareholders Meeting and Provides Update on Its Portfolio Companies July 12, 2017
Biohaven announces closing of initial public offering and full exercise of underwriters’ option to purchase additional shares May 15, 2017
Biohaven files registration statement for proposed public offering of its common shares April 7, 2017
FDA clears Biohaven’s Investigational New Drug Application For BHV-4157 and Portage To Hold Investor Conference Call to Provide Business Update July 5, 2016
Portage’s Biohaven Orphan Drug Designation Request Granted for the Treatment of Spinocerebellar Ataxia March 3, 2016
Portage’s Biohaven Announces Expedited Development Path for BHV-0223 Following Successful Pre-IND Interaction with FDA February 25, 2016
Mr. James Mellon and Dr. Gregory Bailey (“Offerors”) Announce Additional Shares in Portage Biotech Inc. December 14, 2015
Portage’s Biohaven Announce Phase I Pharmacokinetic Study Meets Study Objectives and Supports Advancing BHV-0223 and also Appoints a CEO November 19, 2015
Portage’s Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV-0223 October 6, 2015
Biohaven and Fox Chase Chemical Diversity Center Announce Strategic Alliance in Early Stage Drug Discovery Research October 1, 2015
Portage’s Biohaven Completes Single Dose Phase of Pharmacokinetic Trial with BHV-0223 September 21, 2015
Portage’s PPL Will Advance its Lead Candidate PPL-003 to an IND for Dry Eye Disease and Uveitis August 31, 2015
Portage’s Biohaven Doses First Human Subject in Phase I Trial with Lead Drug Candidate BHV-0223 August 27, 2015
Portage’s Biohaven Acquires Intellectual Property for Portfolio of Prodrugs from ALS Biopharma, LLC August 18, 2015
Portage’s Biohaven Raises US$4.1 Million in First Tranche of Private Placement. Portage Invests $2.5M August 11, 2015
Portage Completes Non-Brokered Private Placement in Two Tranches for Total Proceeds of US$ 5,155,080 June 25, 2015
Portage’s Biohaven to Begin Phase I Study in 3Q 2015 and Readying for Phase III Study Start by Q1 2016 April 22, 2015
Portage’s Biohaven Enters into Exclusive Formulation Agreement and Global License with Catalent for Lead Product March 24, 2015
Portage Announces Further Successful Validation of its New Proprietary Cell Permeable Peptide Platform Technology December 16, 2014
Portage Announces Additional Consultants to Expedite its PPL-003 Development Programs October 6, 2014
Portage’s Biohaven Granted United States Patent for Glutamate Agents in the Treatment of Mental Disorders August 6, 2014
Portage Announces Successful Validation of its New Proprietary Cell Permeable Peptide Platform Technology July 14, 2014
Portage Signs a Collaborative Research and Development Agreement with U.S. National Institute of Health May 15, 2014
Portage’s Biohaven Issued Notice of Allowance: Glutamate Agents in the Treatment of Mental Disorders May 5, 2014
Portage Acquires Majority Interest in Biohaven Pharmaceutical Holding Company Limited January 6, 2014
Juvenescence CEO reveals why its deal with Portage is the smart choice for its longevity IP portfolio March 9, 2021
CEO Spotlight: Portage Biotech CEO Dr. Ian Walters Talks Asset Pipeline, Uplist, and Strategic Initiatives in a $20 Billion Sector December 1, 2020
